Drug lookup | Fillwise

ROPINIROLE

All products: general benefit

Other products in the same Health Canada class (N04B, N04BC) — coverage varies; not interchangeable

Bromocriptine (Parlodel): general benefit, Not a benefit
Amantadine (Symmetrel): general benefit, Not a benefit
Benserazide + levodopa (Prolopa 50-12.5): general benefit
Carbidopa + levodopa (Sinemet CR): general benefit, Limited Use, Not a benefit
Selegiline (Eldepryl): general benefit, Not a benefit
Carbidopa + entacapone + levodopa (Stalevo): limited Use 367

Teva-Ropinirole · DIN 02316862 · 2mg · tablet

General benefitMarketed · checked 2026-09-19

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Teva-Ropinirole · DIN 02316862 Manufacturer: Teva Canada Limited; listing date 2009-09-30 Health Canada: Marketed since 2020-05-22 · brand TEVA-ROPINIROLE · ATC N04BC04 ROPINIROLE · form Tablet · route Oral · ingredients ROPINIROLE (ROPINIROLE HYDROCHLORIDE) 2 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Teva-Ropinirole: Formulary list price $0.6338/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6338 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80236 · Verify on the e-Formulary ↗ (DIN 02316862)

Source record

DIN 02316862: Teva-Ropinirole Raw flags: sec3=Y Item: 920000291; group id 953; item number 2265; lccId None; manufacturer id TEV Source form: Tab; strength: 2mg Recorded listing: General benefit Source prices (unrounded): $0.6338; ministry $0.6338 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02316862 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80236

Interchangeable products

Ran-Ropinirole · DIN 02314061 · $0.6338 ReQuip · DIN 02232568 · not recorded

Shortage status: not checked (no credentials)

Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

LEVODOPA & BENSERAZIDE

· 3 products · General benefit · strengths: 50mg & 12.5mg, 100mg & 25mg, 200mg & 50mg · Cap

LEVODOPA & CARBIDOPA

· 25 products · Listed, not a benefit (5), Limited Use, codes 64, 65 (2), General benefit (18) · strengths: 100mg & 25mg, 200mg & 50mg, 100mg & 10mg, 250mg & 25mg · CR Tab, Tab

SELEGILINE HCL

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 5mg · Tab

LEVODOPA & CARBIDOPA & ENTACAPONE

· 5 products · Limited Use, codes 367 · strengths: 75 & 18.75 & 200mg, 125 & 31.25 & 200mg, 50 & 12.5 & 200mg, 100 & 25 & 200mg, 150 & 37.5 & 200mg · Tab

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:00 and 75 more

Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.

What the Health Canada label says it is for

INDICATIONS AND CLINICAL USE Adults: SPC-ROPINIROLE (Ropinirole Tablets) is indicated in the treatment of the signs and symptoms of idiopathic Parkinson's disease. SPC-ROPINIROLE can be used both as early therapy without concomitant levodopa and as an adjunct to levodopa. Geriatrics (> 65 years of age): Oral clearance of SPC-ROPINIROLE is reduced in patients older than 65 years of age, however the dosing of ropinirole for elderly patients can be titrated in the normal manner. (see ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, Geriatrics). Paediatrics (≤ 18 years of age): The safety and efficacy of Ropinirole Tablets have not been established in children under 18 years of age, therefore SPC-ROPINIROLE is not recommended in this patient population. https://pdf.hres.ca/dpd_pm/00081006.PDF PM date: JUN 26, 2025 Source product: SPC-ROPINIROLE; DIN 02314037; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.